<DOC>
	<DOC>NCT00688623</DOC>
	<brief_summary>To evaluate the preliminary efficacy and safety of RAD001 as monotherapy for first-line treatment of patients with metastatic papillary carcinoma of the kidney.</brief_summary>
	<brief_title>RAMSETE: RAD001 in Advanced and Metastatic Silent Neuro-endocrine Tumors in Europe</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Endocrine Gland Neoplasms</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Inclusion criteria: 1. ≥ 18 years old 2. Patients with advanced (unresectable or metastatic) biopsy proven nonsyndromic neuroendocrine carcinoma, low or intermediate grade 3. Radiological documentation of disease progression within 12 months prior to study entry. If patients received antitumor therapy during the past 12 months, they must have radiological documentation of PD while on or after receiving the therapy 4. Patients may have received previous treatments (chemotherapy, biotherapy, peptidereceptor radionuclide therapy); an overall maximum of 3 systemic treatment is allowed 5. Patients with at least one measurable lesion 6. Patients with an ECOG Performance Status 02 7. Adequate bone marrow function 8. Adequate liver function 9. Adequate renal function 10. Adequate lipid profile Exclusion criteria: 1. Patients with poorly differentiated neuroendocrine carcinoma, highgrade neuroendocrine carcinoma, adenocarcinoid, goblet cell carcinoid and small cell carcinoma 2. Patients with carcinoid with hormone related symptoms (diarrhea ≥ 4 stools per day and/or flushes) 3. Patients with Islet cell carcinomas or pancreatic NET 4. Patients who received prior therapy with VEGF pathway inhibitor within 4 weeks prior to study entry 5. Patients who entered PRRT within 3 months prior to study entry 6. Patients who received CT, biotherapy or radiotherapy within 4 weeks prior to study entry 7. Patients who have previously received systemic mTOR inhibitors 8. Patients with a known hypersensitivity to everolimus or other rapamycins or to its excipients 9. Patients with uncontrolled central nervous system (CNS) metastases 10. Patients receiving chronic systemic treatment with corticosteroids or another immunosuppressive agent 11. Patients with a known history of HIV seropositivity 12. Patients with autoimmune hepatitis 13. Patients with an active, bleeding diathesis 14. Patients who have any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study 15. Patients who have a history of another primary malignancy and off treatment ≤ 3 years, with the exception of nonmelanoma skin cancer and carcinoma in situ of the uterine cervix 16. Female patients who are pregnant or breast feeding, or adults of reproductive potential who are not using effective birth control methods 17. Patients who are using other investigational agents or who had received investigational drugs ≤ 4 weeks prior to study treatment start 18. Patients unwilling to or unable to comply with the protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Neuroendocrine tumors</keyword>
	<keyword>non-functioning neuroendocrine tumors carcinoids</keyword>
	<keyword>non-functioning carcinoids</keyword>
	<keyword>adults</keyword>
	<keyword>everolimus</keyword>
</DOC>